The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer.

Atas E, Berchtold K, Schlederer M, Prodinger S, Sternberg F, Pucci P, Steel C, Matthews JD, James ER, Philippe C, Trachtová K, Moazzami AA, Artamonova N, Melchior F, Redmer T, Timelthaler G, Pohl EE, Turner SD, Heidegger I, Krueger M, Resch U, Kenner L.

Open source

DOI: 10.1186/s12943-025-02320-y
Published: 2025-05-05
Container: Mol Cancer
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12943-025-02320-y,
  title = {The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer.},
  author = {Atas E and  Berchtold K and  Schlederer M and  Prodinger S and  Sternberg F and  Pucci P and  Steel C and  Matthews JD and  James ER and  Philippe C and  Trachtová K and  Moazzami AA and  Artamonova N and  Melchior F and  Redmer T and  Timelthaler G and  Pohl EE and  Turner SD and  Heidegger I and  Krueger M and  Resch U and  Kenner L.},
  year = {2025},
  journal = {Mol Cancer},
  doi = {10.1186/s12943-025-02320-y},
  url = {https://doi.org/10.1186/s12943-025-02320-y}
}

RIS

TY  - JOUR
TI  - The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer.
AU  - Atas E
AU  -  Berchtold K
AU  -  Schlederer M
AU  -  Prodinger S
AU  -  Sternberg F
AU  -  Pucci P
AU  -  Steel C
AU  -  Matthews JD
AU  -  James ER
AU  -  Philippe C
AU  -  Trachtová K
AU  -  Moazzami AA
AU  -  Artamonova N
AU  -  Melchior F
AU  -  Redmer T
AU  -  Timelthaler G
AU  -  Pohl EE
AU  -  Turner SD
AU  -  Heidegger I
AU  -  Krueger M
AU  -  Resch U
AU  -  Kenner L.
PY  - 2025
JO  - Mol Cancer
DO  - 10.1186/s12943-025-02320-y
UR  - https://doi.org/10.1186/s12943-025-02320-y
ER  -

APA

E, A., K, B., M, S., S, P., F, S., P, P., C, S., JD, M., ER, J., C, P., K, T., AA, M., N, A., F, M., T, R., G, T., EE, P., SD, T., I, H., M, K., U, R., & L., K. (2025). The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer.. Mol Cancer. https://doi.org/10.1186/s12943-025-02320-y

Source records

europe-pmc · retrieved 2026-09-27T05:06:13.890Z
doaj · retrieved 2026-09-27T05:06:13.905Z